Jump to content

Nandrolone nonanoate

Add links
From Wikipedia, the free encyclopedia
Nandrolone nonanoate
Clinical data
Other names19-Nortestosterone 17β-nonanoate; Nandrolone pelargonate; 19-Nortestosterone 17β-pelargonate
Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen
Identifiers
  • [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] nonanoate
CAS Number
UNII
Chemical and physical data
FormulaC27H42O3
Molar mass414.630 g·mol−1
3D model (JSmol)
  • CCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
  • InChI=1S/C27H42O3/c1-3-4-5-6-7-8-9-26(29)30-25-15-14-24-23-12-10-19-18-20(28)11-13-21(19)22(23)16-17-27(24,25)2/h18,21-25H,3-17H2,1-2H3/t21-,22+,23+,24-,25-,27-/m0/s1 AuxInfo=1/0/N:1,30,2,3,4,5,6,7,8,18,23,17,24,14,13,27,28,20,19,21,25,26,16,15,12,9,29,22,10,11/it:im/rA:30CCCCCCCCCOOCCCCCCCCCCOCCCCCCCC/rB:s1;s2;s3;s4;s5;s6;s7;s8;d9;s9;p11;s12;s13;p14;s15;N16;s17;s18;d19;s20;d21;s21;s23;s19n24;s16s25;P26;s27;s12s15s28;P29;/rC:-11.2241,.7601,0;-9.8904,-.0099,0;-8.5567,.7601,0;-7.223,-.0099,0;-5.8893,.7601,0;-4.5557,-.0099,0;-3.222,.7601,0;-1.8883,-.0099,0;-.5546,.7601,0;-.5546,2.3001,0;.7791,-.0099,0;2.1127,.7601,0;2.2737,2.2917,0;3.7801,2.6118,0;4.5501,1.2782,0;6.0564,.958,0;7.0869,2.1024,0;8.5932,1.7822,0;9.0691,.3176,0;10.5754,-.0026,0;11.0513,-1.4672,0;12.5577,-1.7874,0;10.0209,-2.6117,0;8.5145,-2.2915,0;8.0386,-.8268,0;6.5323,-.5067,0;5.5018,-1.6511,0;3.9955,-1.3309,0;3.5196,.1337,0;2.3751,-.8967,0;
  • Key:UVVFTQBZOQSECA-QNTYDACNSA-N

Nandrolone nonanoate, also known as nandrolone pelargonate or as 19-nortestosterone 17β-nonanoate, is an androgen and anabolic steroid and an androgen ester—specifically, the C17β nonanoate (pelargonate) ester of nandrolone (19-nortestosterone)—which was studied but was never marketed.[1][2][3][4][5][6][7]

References

[edit]
  1. ^ Chaudry AQ, James KC (February 1974). "A Hansch analysis of the anabolic activities of some nandrolone esters". J Med Chem. 17 (2): 157–61. doi:10.1021/jm00248a003. PMID 4809250.
  2. ^ Chaudry MA, James KC, Ng CT, Nicholls PJ (December 1976). "Anabolic and androgenic activities, in rat, of some nandrolone and androstanolone esters". J Pharm Pharmacol. 28 (12): 882–5. doi:10.1111/j.2042-7158.1976.tb04085.x. PMID 12263. S2CID 20546783.
  3. ^ Chaudry MA (1983). "Preparation and characterization some of anabolic steroids". Journal of Pharmacy (Lahore). 4 (1–2): 13–17. ISSN 0253-8288. Butyrate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, and undecanoate esters of testosterone and nandrolone were prepd. and characterized.
  4. ^ Chaudry MA (1983). "A realistic method for the evaluation of anabolic androgenic activity of some nandrolone esters". Journal of Pharmacy (Lahore). 4 (1–2): 51–62. ISSN 0253-8288. The short-comings of the various methods used for detg. anabolic-androgenic activities were discussed, and a realistic method was developed for the comparative studies. The limitation of using the wt. gain of the target organs after administration of the hormone, which is time-dependent, was highlighted. The cumulative wt. (mg day) was recommended; it is independent of time, provided the expt. is carried out until the sample response reaches a plateau. This method provides a basis for obtaining anabolic-androgenic percentage dissocn. The method is applied to a no. of nandrolone esters.
  5. ^ Ruelle P, Farina-Cuendet A, Kesselring UW (November 1997). "The mobile order solubility equation applied to polyfunctional molecules: The non-hydroxysteroids in aqueous and non aqueous solvents". Int J Pharm. 157 (2): 219–232. doi:10.1016/s0378-5173(97)00240-8. PMID 10477819.
  6. ^ Joseph R. Robinson (1978). Sustained and Controlled Release Drug Delivery Systems. M. Dekker. p. 428. ISBN 978-0-8247-6715-0.
  7. ^ Chien YW (1981). "Long-acting parenteral drug formulations". J Parenter Sci Technol. 35 (3): 106–139. PMID 6113276.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nandrolone_nonanoate&oldid=1184634071"